A new wave of pharma mergers could put innovative drugs in the pipeline

A new wave of pharmaceutical industry mergers may be on the horizon, driven in part by the $1.3 trillion in overseas cash that U.S. corporations currently hold. If policymakers provide a tax holiday on repatriation of these funds, some experts say that U.S. pharmaceutical companies would be flush with cash and could likely spend a meaningful portion of this windfall on mergers.